Highest-materiality recent filing
PetMed Q4 sales fall 15.6% to $42.8M; FY net loss widens to $57.3M on goodwill impairment
Q4 net sales $42.8M (down 15.6% YoY); FY net sales $179M (down 21.1%) on lower prescription sales.
PetMed Express dismisses RSM as auditor, hires Baker Tilly; cites material weaknesses in controls
Audit Committee dismissed RSM US LLP as independent auditor effective after interim reviews; Baker Tilly US LLP engaged for FY2026.
PetMed Express extends shareholder rights plan to December 2026
Rights plan expiration extended from December 2, 2025 to December 2, 2026.
PetMed Express warns Q2 net sales down ~25% YoY; receives Nasdaq delisting notice
Preliminary Q2 net sales estimated at $43.4M-$44.5M vs $58.0M (restated) prior year.
PetMed Express FY2025 net sales $227M, net loss $6.3M; Q1/Q2 filings delayed
Net sales of $227.0M for FY2025 below preliminary range of $231.6M-$233.6M due to restatement of promotional sales reimbursements to cost of sales.
PetMed Express to restate FY2024, FY2023; investigation reveals revenue errors, former CEO/CFO out
Net sales overstated by ~$7.0M in FY2024 and ~$9.0M in FY2023 due to vendor payment misclassification; no net income impact.
PetMed Express receives Nasdaq non-compliance notice; plan due Sept 1, 2025
Nasdaq notified PetMed for late filing of FY2025 10-K and Q1 FY2026 10-Q, violating Listing Rule 5250(c)(1).
CEO Sandra Campos and CFO Robyn D'Elia resigned Aug 11, 2025; severance includes 13-month salary continuation and accelerated RSU vesting.
PetMed Express receives Nasdaq deficiency notice for late FY2025 10-K filing
Received Nasdaq notice on July 2, 2025 for non-compliance with Listing Rule 5250(c)(1) due to delayed annual report.
10-K filing delayed beyond July 1 extension; Audit Committee investigating anonymous whistleblower reports.
PetMed Express prelim Q4 sales $51-53M vs $66.5M; net loss widens to $10M; delays 10-K
Q4 net sales estimated $51.1-53.1M (down ~21% YoY); net loss $9.9-10.4M vs $5.0M prior year.
PetMed Express Q3 net sales $53M; Adj. EBITDA rises to $2M from $0.9M
Net sales of $53.0 million in Q3 fiscal 2025.
PetMed Express adopts limited-duration shareholder rights plan (poison pill) with 12.5% trigger
Board cites recent significant stock accumulations by certain shareholders; stock not reflecting intrinsic value.
PetMed Express adopts 2024 Inducement Incentive Plan, grants RSUs to CFO
Plan reserves 350,000 shares for equity awards to new employees as employment inducements under Nasdaq Rule 5635(c)(4).
PetMed Express Appoints Robyn D'Elia as Chief Financial Officer
Robyn D'Elia appointed CFO effective September 16, 2024; reports to CEO Sandra Campos.
PetMed Express Q1 net income $3.8M on $8.7M stock comp reversal; sales down 13%
Net sales $68M, down 13% YoY; net income $3.8M ($0.18 diluted) vs loss of $(1.1M) ($(0.06)) prior year.
PetMed Express Q4 net loss widens to $5.0M; FY net loss $7.5M vs prior year profit
Q4 net sales $66.5M (+6.6% YoY) driven by PetCareRx acquisition; legacy PetMeds sales declined.
PetMed Express names Sandra Campos CEO; Hulett resigns with severance
Matt Hulett resigned as CEO, President, and director on April 29; will remain as advisor through Aug 30.
PetMed Express Q3 net loss $2.0M; completes sales tax restatement
Revenue $65.3M, up 11% YoY, driven by PetCareRx acquisition; legacy sales declined.
PetMed Express receives Nasdaq deficiency notice for delayed Q3 filing due to restatement
Nasdaq notice on Feb 13, 2024 for non-compliance with Listing Rule 5250(c)(1) due to late Form 10-Q (quarter ended Dec 31, 2023).
PetMeds restates FY2021-2023 financials, preliminary Q3 sales up 11% YoY to $65.3M
Restatement covers FY2021-2023 and Q1/Q2 FY2024 due to sales tax and deferred tax errors.
PetMed Express Q2 net loss of $70k; suspends quarterly dividend to invest in growth
Net sales $71.0M (+9% YoY); net loss $70k vs $2.6M income; diluted EPS ($0.00) vs $0.13.
PetMed Express Q1 net sales $78.2M (+11.5% YoY); net loss $(0.9)M; declares $0.30 dividend
Net sales $78.2M, up 11.5% YoY from $70.2M; net loss $(0.9)M ($0.04 diluted loss) vs net income $2.8M ($0.14 EPS) in prior year.
PetMed Q4 sales $62.4M (-5% YoY), net loss $5.1M; acquires PetCareRx, declares $0.30 dividend
Q4 sales $62.4M (-5% YoY); net loss $5.1M ($0.25 loss per share) vs net income $6.1M last year.
PetMed Express Q4 net loss $5.1M, revenue down 5.4%; declares $0.30 dividend
Q4 net loss $(5.1)M ($0.25 diluted EPS) vs net income $6.1M ($0.30) prior year.
PetMed Express closes $36M all-cash acquisition of PetCareRx
Total consideration of approx $36M in all-cash transaction.
PetMed Express reports Q3 net loss of $19K; revenue down 3% to $58.9M; declares $0.30 dividend
Net sales $58.9M (down 3% YoY); net loss $19K vs net income $4.3M prior year.
PetMed Express announces definitive agreement to acquire PetCareRx
Entered into Agreement and Plan of Merger to acquire PetCareRx, Inc.
PetMeds acquires PetCareRx for $36M cash; adds ~200K customers, ~$42M revenue
All-cash deal $36M plus working capital adjustments; expected close Q1 2023.
PetMed Q2 net sales $65.4M (-3% YoY), EPS $0.13 vs $0.31; dividend $0.30/share
Net income fell to $2.6M ($0.13 diluted) from $6.3M ($0.31) a year ago; included $1.3M in non-recurring items.
On April 9, 2025, the Board of Directors (the “Board”) of PetMed Express, Inc. (the “Company”) approved the appointment of Peter Batushansky to serve as a director of the Company beginning April 9, 2025.
Dr. Gian Fulgoni, longtime Board member and former Chairman, has communicated his intention to retire from the Board when his term expires at the 2025 annual shareholders’ meeting.
On September 11, 2024, the Board of Directors of PetMed Express, Inc. (“Company”) appointed Robyn D’Elia to serve as the Company’s Chief Financial Officer and to assume the duties of principal financial officer effective September 16, 2024 (“Effective Date”).
On August 2, 2024, the Board of Directors of PetMed Express, Inc. (“Company”) appointed Doug Krulik to serve as the Company’s Chief Accounting Officer to assume the duties of principal accounting officer and interim-principal financial officer effective August 19, 2024 (“Effective Date”).
On June 20, 2024, the Board of Directors (the “Board”) of PetMed Express, Inc. (the “Company”) approved the appointment of Leah A. Solivan to serve as a director of the Company beginning June 24, 2024.
On May 31, 2024, PetMed Express, Inc. (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) with Christine Chambers, the Company’s Chief Financial Officer, Treasurer, and Secretary, pursuant to which the Company and Ms. Chambers agreed to the mutual termination of Ms. Chambers’ employment with the Company following a transition period.
On May 16, 2024, the Board of Directors (the “Board”) of PetMed Express, Inc. (the “Company”), appointed Justin L. Mennen to serve as a director of the Company beginning June 3, 2024.
the Company appointed Sandra Campos, an existing director of the Company, as the Company’s new Chief Executive Officer and President.
Mr. Hulett resigned as President and Chief Executive Officer, and also as a director, of the Company effective April 29, 2024
On May 17, 2023, the Board of Directors ("Board") of PetMed Express, Inc. (the "Company") approved the appointment of Sandra Y. Campos as a director on its Board
On May 16, 2023, Jodi Watson informed the Board that she does not wish to stand for re-election to the Board when her term expires at the Company's 2023 Annual Meeting of Shareholders on August 3, 2023
On August 3, 2022, PetMed Express, Inc. (the “Company”) entered into an employment agreement (“Employment Agreement”) with Christine Chambers to set forth the terms and conditions of Ms. Chambers’ employment as Chief Financial Officer of the Company.
Max materiality 0.85 · Median 0.60 · Most common event earnings